IDEAYA Biosciences Target of Unusually Large Options Trading (NASDAQ:IDYA)
IDEAYA Biosciences (NASDAQ: IDYA) recently experienced unusually large options trading, with investors buying 24,287 call options, a 2,391% increase over typical volume, indicating significant bullish sentiment. The company has a "Moderate Buy" consensus rating from analysts with an average price target of $48.69, and reported strong quarterly earnings, beating revenue and EPS estimates. Insider activity also shows confidence, with Director Jeffrey Stein purchasing 50,000 shares.
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer
IDEAYA Biosciences has enrolled the first patient in its Phase 1 trial for IDE574, a potential first-in-class oral small molecule. This drug is a dual inhibitor of KAT6 and KAT7, targeting solid tumor indications including breast, prostate, colorectal, and lung cancers. The trial will evaluate the safety, efficacy, and pharmacokinetics of IDE574 as a monotherapy.
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer
IDEAYA Biosciences has initiated a Phase 1 clinical trial for IDE574, a novel dual inhibitor targeting KAT6/7, with the first patient now enrolled. This potential first-in-class treatment aims to address a wide range of solid tumor indications, including breast, prostate, colorectal, and lung cancers. The announcement highlights the company's progress in advancing its oncology pipeline.
Breast to lung cancers: IDEAYA puts IDE574 into human testing
IDEAYA Biosciences announced the first patient enrolled in its Phase 1 trial for IDE574, a potential first-in-class dual inhibitor of KAT6 and KAT7. This oral therapy targets solid tumors including breast, prostate, colorectal, and lung cancer, aiming for monotherapy efficacy and durable anti-tumor responses. Preclinical data show high potency and selectivity, with further details to be presented at AACR 2026.
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer
IDEAYA Biosciences has initiated a Phase 1 trial for IDE574, a potential first-in-class dual inhibitor targeting KAT6/7, for solid tumor indications including breast, prostate, colorectal, and lung cancer. This oral small molecule aims to overcome resistance mechanisms and tumor heterogeneity, demonstrating superior preclinical efficacy compared to KAT6-selective inhibitors. The trial will assess IDE574's safety, efficacy, and pharmacokinetics as a monotherapy.
IDYA PE Ratio & Valuation, Is IDYA Overvalued
IDEAYA Biosciences Inc (IDYA) is currently categorized as "Undervalued" based on its forward PS ratio of 23.79 compared to its five-year average. The fair price for IDYA is estimated to be between $34.01 and $121.49, with the current price of $32.74 indicating it is undervalued by 3.73%. Despite a P/S ratio above the industry average, this premium is considered sustainable due to robust revenue growth.
Why IDEAYA Biosciences (IDYA) Is Up 7.5% After Early Data From First-in-Class Cancer Combo
IDEAYA Biosciences (IDYA) saw its shares rise 7.5% after announcing the first patient-in for a global Phase 1 trial combining IDE849 and IDE161 for DLL3-upregulated solid tumors, including small cell lung cancer. Early clinical activity, such as partial responses in heavily pre-treated SCLC patients, has been observed. This development, while not displacing uveal melanoma data as a near-term catalyst, strengthens IDEAYA's long-term strategy of rational ADC plus DDR combinations for registrational opportunities, despite associated complexities and costs.
IDEAYA Biosciences, Inc. $IDYA Position Decreased by JPMorgan Chase & Co.
JPMorgan Chase & Co. significantly reduced its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 61.0% in the third quarter, now holding 174,265 shares valued at $4.742 million. Despite this, IDEAYA Biosciences surpassed earnings expectations, reporting an EPS of -$0.94 against an estimated -$1.03 and revenue of $21.75 million, significantly higher than the estimated $5.95 million. Analyst sentiment remains largely bullish, with an average target price of $48.69, and company director Jeffrey Stein recently increased his holdings.
IDEAYA Biosciences Achieves 119.91% Growth, Establishing It as a Multibagger in Biotechnology Sector
IDEAYA Biosciences, Inc. has achieved remarkable performance, with a nearly 120% return over the past year, significantly outperforming the S&P 500. The company also demonstrated strong financial health, with a 55.37% year-on-year increase in net sales and a net profit of approximately $36 million in the first half. With a market capitalization of nearly $2.93 billion, IDEAYA Biosciences is establishing itself as a multibagger in the biotechnology sector.
A Look At IDEAYA Biosciences (IDYA) Valuation After Early IDE849 And IDE161 Combination Trial Activity
IDEAYA Biosciences (IDYA) recently reported the first patient enrolled in a Phase 1 trial combining IDE849 and IDE161, influencing its stock valuation. Despite a 1-year total shareholder return near 100% and an analyst target above its current share price, the company's valuation presents mixed signals. The stock trades at a premium Price-to-Sales ratio compared to the industry average, yet Simply Wall St's DCF model suggests it is significantly undervalued based on future cash flow.
Wedbush Reiterates Outperform Rating for IDEAYA Biosciences (NASDAQ:IDYA)
Wedbush reiterated an "Outperform" rating for IDEAYA Biosciences (NASDAQ:IDYA) with a $52 price target, indicating a 56% potential upside. This follows IDEAYA beating quarterly earnings and revenue estimates, alongside a significant insider share purchase by Director Jeffrey Stein. The company has a "Moderate Buy" consensus rating from analysts, with a target price of $48.69.
37,595 Shares in IDEAYA Biosciences, Inc. $IDYA Acquired by Tudor Investment Corp ET AL
Tudor Investment Corp ET AL has acquired a new stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA), purchasing 37,595 shares valued at approximately $1.02 million. Additionally, Director Jeffrey Stein significantly increased his holding by acquiring 50,000 shares for $1.65 million. The company reported strong Q4 earnings, surpassing analyst estimates for EPS and revenue, and holds a "Moderate Buy" consensus rating with a target price of $48.69.
IDEAYA moves new cancer drug combo into patients after early lung tumor responses
IDEAYA Biosciences announced it has initiated a Phase 1 combination study of its cancer drug IDE849 (a DLL3-targeting TOP1 ADC) and IDE161 (a PARG inhibitor) for DLL3-upregulated solid tumors, including small cell lung cancer (SCLC), neuroendocrine tumors (NETs), neuroendocrine carcinomas (NECs), and melanoma. This follows promising early monotherapy results of IDE849, which showed multiple partial responses in an expansion cohort, including 3 out of 4 SCLC patients. The company expects to provide a clinical data update for both monotherapy and combination treatments in the second half of 2026.
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma
IDEAYA Biosciences has initiated a Phase 1 clinical trial evaluating the combination of IDE849 (a DLL3 TOP1 ADC) and IDE161 (a PARG inhibitor) for DLL3 upregulated solid tumors, including SCLC, NETs, NECs, and melanoma. This first-in-class combination aims to enhance the efficacy and durability of TOP1 ADCs by leveraging the DNA damage repair pathway. The company anticipates providing an update on both monotherapy IDE849 and the IDE849/IDE161 combination clinical data in the second half of 2026.
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma
IDEAYA Biosciences announced that the first patient has been enrolled in a Phase 1 clinical trial evaluating the combination of IDE849, a DLL3-targeting Topo-I-payload antibody drug conjugate, and IDE161, a PARG inhibitor, for DLL3-upregulated solid tumors like SCLC and melanoma. The company expects to provide an update on both monotherapy IDE849 and the IDE849/IDE161 combination clinical data in the second half of 2026. This combination aims to enhance the efficacy of TOP1 ADCs by inducing the accumulation of TOP1 lesions, leveraging IDEAYA's expertise in DNA damage repair.
Is It Too Late To Consider IDEAYA Biosciences (IDYA) After Its Strong Multi Year Run
This article analyzes IDEAYA Biosciences (IDYA) to determine if it still offers value after significant multi-year gains despite recent short-term pullbacks. Using a Discounted Cash Flow (DCF) model, Simply Wall St suggests IDYA is significantly undervalued, estimating an intrinsic value far above its current share price. However, its Price-to-Sales (P/S) ratio indicates it might be overvalued compared to industry averages and Simply Wall St's proprietary "Fair Ratio."
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences announced the grant of non-qualified stock options to two new employees. These grants, totaling 49,000 shares, were made under the company's 2023 Employment Inducement Incentive Award Plan and comply with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $32.09, vest over four years, and are intended to induce individuals to join IDEAYA.
Vanguard disaggregates holdings; affiliates to report separately (IDYA)
The Vanguard Group has filed an amended Schedule 13G/A for Ideaya Biosciences Inc (IDYA), reporting 0 shares beneficially owned and 0% of the class. This change follows an internal realignment on January 12, 2026, where Vanguard's subsidiaries will now report ownership separately in accordance with SEC Release No. 34-39538. Vanguard clarifies that it no longer has beneficial ownership over securities held by these disaggregated subsidiaries.
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences announced the grant of non-qualified stock options to two new employees under its 2023 Employment Inducement Incentive Award Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). These options cover 49,000 shares of common stock, with an exercise price equal to the closing price on the grant date ($32.09 per share). The options will vest over four years, subject to continued employment, aiming to attract and retain talent for the precision medicine oncology company.
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences announced that its Compensation Committee granted non-qualified stock options to two new employees to purchase 49,000 shares of the company's common stock. These grants were made under the 2023 Employment Inducement Incentive Award Plan, per Nasdaq Listing Rule 5635(c)(4), to incentivize their employment. The stock options have an exercise price of $32.09,vest over four years, and are contingent on continued service to IDEAYA.
Two new IDEAYA hires receive options for 49,000 shares total
IDEAYA Biosciences announced it granted non-qualified stock options for a total of 49,000 shares to two new employees on March 26, 2026. The options, granted under the 2023 Inducement Plan, have an exercise price of $32.09, matching the closing price on the grant date, and will vest over four years. This move aligns with Nasdaq Listing Rule 5635(c)(4) for talent recruitment and retention.
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences announced that its Compensation Committee granted non-qualified stock options to purchase 49,000 shares of the company's common stock to two new employees. These grants were made under the 2023 Employment Inducement Incentive Award Plan as a material inducement for employment, in compliance with Nasdaq Listing Rule 5635(c)(4). The stock options have a 10-year term, an exercise price of $32.09 per share, and will vest over four years.
Does IDEAYA (IDYA) Use OptimUM-02 Timing To Reframe Its Core Clinical Pipeline Story?
IDEAYA Biosciences is drawing investor attention to the upcoming topline data from its Phase 2/3 OptimUM-02 trial with a clarified timeline and planned webcast. The outcome of this trial, focusing on first-line metastatic uveal melanoma, is seen as a significant near-term catalyst that will shape perceptions of the company's clinical pipeline and validate management's R&D priorities. Despite a recent share pullback, investors should be aware of the strong reliance on the OptimUM-02 results, as the stock may still trade above its fair value with substantial losses.
Assessing IDEAYA Biosciences (IDYA) Valuation After Recent Share Price Weakness
IDEAYA Biosciences (IDYA) has experienced recent share price weakness, with a 3.4% decline in one day and a 9.05% decline over seven days, despite strong long-term returns. The stock trades at US$31.64, below an analyst target of US$50.00, suggesting a potential intrinsic discount of 87.8%. While its Price-to-Sales ratio of 12.7x indicates overvaluation compared to industry averages, a Discounted Cash Flow (DCF) model suggests the stock is undervalued, trading significantly below its estimated future cash flow value of US$259.43.
Assessing IDEAYA Biosciences (IDYA) Valuation After Recent Share Price Weakness
IDEAYA Biosciences (IDYA) has seen recent share price weakness, with a 3.4% decline in one day and a 9.05% decline over seven days, despite strong longer-term shareholder returns. The company's valuation presents mixed signals; while its Price-to-Sales ratio of 12.7x suggests it is overvalued compared to industry peers and its estimated fair level, a Discounted Cash Flow (DCF) model indicates significant undervaluation with a potential upside. Investors are encouraged to consider both the P/S ratio and DCF model alongside clinical, regulatory, and partnership risks.
IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Down 6.1% - Here's Why
IDEAYA Biosciences (NASDAQ:IDYA) experienced a 6.1% stock price drop on Monday, trading at $30.74, despite largely bullish analyst ratings and a consensus "Moderate Buy" with a target price of $48.69. The company recently reported a revenue and EPS beat and saw a significant insider stock purchase. Institutional ownership is high at 98.29%, with several large investors increasing their stakes.
IDEAYA Biosciences Opens Weak with 5.14% Gap Down Amid Market Concerns
IDEAYA Biosciences, a small-cap pharmaceuticals and biotechnology company, experienced a 5.14% gap down amid a broader market decline, despite a positive 5.92% performance over the past month. The company has a market capitalization of USD 3,055 million, a negative return on equity, and a unique debt-to-equity ratio of -0.62. Technical indicators show mixed signals, with a mildly bearish weekly MACD but a bullish monthly outlook.
IDEAYA Biosciences Sees Unusually High Options Volume (NASDAQ:IDYA)
IDEAYA Biosciences (NASDAQ:IDYA) experienced unusually high put options trading volume, with 9,704 put options acquired, indicating increased bearish sentiment. This comes despite the company reporting better-than-expected quarterly earnings and revenue. Insider Jeffrey Stein recently increased his stake by purchasing 50,000 shares, and institutional ownership remains high at nearly 98.29%, with several funds increasing their positions.
IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial
IDEAYA Biosciences announced its participation in upcoming investor relations events and provided updated guidance for the topline data release from its Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma. The database lock for the darovasertib trial is projected for the first half of April, with data analysis to follow. The company will host an investor and analyst webcast and participate in conferences in May 2026.
IDEAYA delays darovasertib trial results to mid-April By Investing.com
IDEAYA Biosciences announced a delay in the topline results for its Phase 2/3 OptimUM-02 trial of darovasertib until mid-April, moving the database lock to the first half of April. Despite this, the company's stock has seen a 78% return over the past year, and InvestingPro analysis suggests it is currently undervalued with a strong financial position. IDEAYA continues to advance its oncology pipeline, recently enrolling patients in new Phase 1 trials and appointing a Chief Development Officer.
IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial
IDEAYA Biosciences announced updated guidance for its Phase 2/3 OptimUM-02 trial, with the database lock for topline darovasertib results now projected for the first half of April 2026. The company will host an investor and analyst webcast following the data analysis and will participate in the Bank of America Merrill Lynch Health Care Conference and the Stifel 2026 Targeted Oncology Virtual Forum in May 2026. These events will provide further details on their precision medicine oncology pipeline, including targeted therapeutics for cancer.
Cancer trial readout nears as IDEAYA targets first-half April lock
IDEAYA Biosciences announced updated timing for topline results from its Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma, projecting a database lock in the first half of April. This will be followed by data analysis and an investor webcast. Additionally, IDEAYA will participate in two investor conferences in May 2026 to discuss these results.
IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial
IDEAYA Biosciences announced upcoming investor relations events and provided updated guidance for the topline data release from its Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma. The company expects the database lock for the trial in the first half of April, with a subsequent investor and analyst webcast planned for the data analysis. IDEAYA also confirmed participation in the Bank of America Merrill Lynch Health Care Conference and the Stifel 2026 Targeted Oncology Virtual Forum in May 2026.
IDEAYA Biosciences Experiences Revision in Stock Evaluation Amid Strong Market Performance
IDEAYA Biosciences has shown impressive market performance, outperforming the S&P 500 with a 76.50% return over the past year and 117.48% over three years. While monthly technical indicators suggest bullish sentiment, weekly trends show some bearishness. The company, a small-cap player in Pharmaceuticals and Biotechnology, currently trades at $32.60.
Is IDEAYA Biosciences (IDYA) Priced Fairly After A 76.8% One-Year Share Gain?
IDEAYA Biosciences (IDYA) has seen a significant 76.8% gain over the past year. While a Discounted Cash Flow (DCF) analysis suggests the stock is materially undervalued by 85.9%, its Price-to-Sales (P/S) ratio of 13.09x is above the industry average and Simply Wall St's Fair Ratio of 3.31x, indicating it is overvalued by this metric. Investors are encouraged to use Simply Wall St's "Narratives" feature to form their own valuation based on individual assumptions for future revenue, earnings, and margins.
IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs
IDEAYA Biosciences announced upcoming presentations at the AACR 2026 Annual Meeting, showcasing preclinical data from three clinical-stage pipeline programs: IDE034, IDE574, and IDE892. These programs are designed as potential first-in-class therapies targeting various cancer mechanisms, including TOP1 antibody-drug conjugates, synthetic lethality, and epigenetic modulation. The company is currently conducting Phase 1 clinical studies for these candidates across a broad range of solid tumor indications.
IDEAYA Biosciences (IDYA) Gets a Buy from Mizuho Securities
Mizuho Securities analyst Graig Suvannavejh reiterated a Buy rating on IDEAYA Biosciences (IDYA) with a price target of $46.00. This follows another Buy rating from Wedbush's Robert Driscoll, although TipRanks – xAI maintained a Hold rating. The company recently reported Q4 revenue of $10.88 million and a GAAP net loss of $83.27 million.
Barclays Initiates Coverage of IDEAYA Biosciences (IDYA) with Overweight Recommendation
Barclays has initiated coverage of IDEAYA Biosciences (IDYA) with an "Overweight" rating. The firm has set a price target of $60.00 for the biotechnology company, indicating confidence in its future performance.
IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs
IDEAYA Biosciences, Inc. announced upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting in April 2026. The presentations will showcase preclinical data for three clinical-stage programs: IDE034, a PTK7/B7H3 bi-specific TOP1 ADC; IDE574, a dual KAT6 and 7 inhibitor; and IDE892, an MTA-cooperative PRMT5 inhibitor. These programs are being evaluated in Phase 1 clinical studies for various solid tumor indications, with a focus on delivering monotherapy efficacy and rational combinations.
Three experimental cancer programs to watch at April's big AACR meeting
IDEAYA Biosciences (NASDAQ: IDYA) announced it will present preclinical data for three of its clinical-stage pipeline programs at the AACR Annual Meeting in April 2026. These programs, IDE034, IDE574, and IDE892, are all in Phase 1 clinical studies targeting various solid tumors. The presentations will highlight new data on their mechanisms and potential for treating cancer.
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Consensus Recommendation of "Moderate Buy" by Brokerages
IDEAYA Biosciences (NASDAQ:IDYA) has received a "Moderate Buy" consensus rating from seventeen research firms, with an average one-year price target of $48.69. The company recently reported strong quarterly results, beating EPS and revenue estimates, and a director, Jeffrey Stein, significantly increased his stake by purchasing 50,000 shares. Insider ownership stands at approximately 2.5%, while institutional investors hold 98.29% of the company's stock.
IDEAYA Biosciences, Inc. $IDYA Shares Purchased by Cinctive Capital Management LP
Cinctive Capital Management LP significantly increased its stake in IDEAYA Biosciences (NASDAQ:IDYA) by 193.9% in the third quarter, now owning 49,946 shares worth $1,359,000. Other institutional investors have also adjusted their holdings, with 98.29% of the stock owned by institutions and hedge funds. The company recently reported better-than-expected quarterly earnings and has an average "Moderate Buy" rating from analysts with a consensus target price of $48.69.
A Look At IDEAYA Biosciences (IDYA) Valuation After IDE892 Trial Enrollment And Pipeline Refocus
IDEAYA Biosciences (IDYA) recently initiated patient enrollment for its Phase 1 IDE892 trial and updated its precision oncology pipeline. The company's stock has seen significant gains, and while its Price-to-Sales (P/S) ratio of 13.3x suggests overvaluation compared to industry averages, a Discounted Cash Flow (DCF) model indicates the stock is trading well below its estimated fair value of $209.31, leading to conflicting valuation signals for investors.
A Look At IDEAYA Biosciences (IDYA) Valuation After IDE892 Trial Enrollment And Pipeline Refocus
IDEAYA Biosciences (IDYA) recently enrolled its first patient in the Phase 1 IDE892 trial and updated its oncology pipeline focus, leading to a 78.09% share price increase over the last year. While the company's Price-to-Sales (P/S) ratio of 13.3x suggests it is overvalued compared to industry averages and its own estimated fair P/S of 3.3x, a Discounted Cash Flow (DCF) model indicates a significant undervaluation with a fair value of $209.31 against a current trading price of $33.09. Investors are advised to consider both valuation signals and underlying data, including potential risks and rewards, before making investment decisions.
IDEAYA Biosciences, Inc. $IDYA Position Increased by Baker BROS. Advisors LP
Baker BROS. Advisors LP significantly increased its stake in IDEAYA Biosciences (NASDAQ:IDYA) by 54.6% in the third quarter of 2025, now holding 3.27 million shares valued at approximately $89.13 million. This comes as analysts maintain a "Moderate Buy" consensus rating with a price target of $48.69, following the company's strong revenue beat and narrower-than-expected EPS loss. Additionally, IDEAYA Biosciences Director Jeffrey Stein recently increased his personal stake by purchasing 50,000 shares for over $1.6 million, signaling strong insider confidence.
Is IDEAYA Biosciences (IDYA) Quietly Assembling a Focused MTAP-Deletion Oncology Franchise?
IDEAYA Biosciences is strategically focusing its oncology pipeline on MTAP-deletion and CDKN2A-deficiency, recently enrolling the first patient in its Phase 1 trial for IDE892. This move includes deprioritizing previous studies to concentrate on genetically defined tumor types. While the company's shares have seen gains, its valuation and future depend heavily on clinical trial execution and readouts for its lead programs.
IDEAYA Biosciences: Expanding Precision Oncology Platform and Refocused MTAP Strategy Support Buy Rating
LifeSci Capital analyst Charles Zhu maintained a Buy rating on IDEAYA Biosciences with a price target of $62.00, citing the company's expanding precision oncology platform and strategic capital deployment. Zhu highlighted the first-patient dosing of IDE892 and the reallocation of resources towards wholly-owned MTAP-deletion assets as key drivers. Additionally, upcoming Phase 2b/3 OptiMUM-02 data for metastatic uveal melanoma is anticipated as a near-term catalyst.
Ideaya Biosciences Announces First-Patient-In For Phase 1 Trial Of IDE892
Ideaya Biosciences has announced that the first patient has been enrolled in its Phase 1 trial for the drug IDE892. This marks a significant step forward in the development of the compound. The news was reported by Refinitiv.
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update
IDEAYA Biosciences has initiated a Phase 1 clinical trial for IDE892, a PRMT5 inhibitor targeting MTAP-deleted solid tumors, including NSCLC and pancreatic cancer. The company also provided an update on its MTAP and CDKN2A pipeline, including plans for combination therapy with IDE397 and a first-in-class CDKN2A candidate. IDEAYA is strategically prioritizing its proprietary MTAP-deleted and CDKN2A pipeline, leading to the deprioritization of combination activities with Trodelvy.
(IDYA) as a Liquidity Pulse for Institutional Tactics
The article provides an analysis of Ideaya Biosciences Inc. (NASDAQ: IDYA) for institutional tactics, indicating a strong overweight bias across all horizons. It highlights an exceptional 40.1:1 risk-reward setup and outlines specific position, momentum breakout, and risk hedging trading strategies. The analysis is supported by AI-generated signals and multi-timeframe signal analysis, including near-term, mid-term, and long-term perspectives.
